심혈관 치료제 시장 : 약물 유형, 적응증, 투여 경로, 구매 형태, 최종 사용자별 - 세계 예측(2025-2030년)

The Cardiovascular Drugs Market was valued at USD 82.65 billion in 2023, expected to reach USD 90.13 billion in 2024, and is projected to grow at a CAGR of 9.15%, to USD 152.61 billion by 2030.

The cardiovascular drugs market encompasses a wide range of medications used to treat various heart-related conditions such as hypertension, heart failure, arrhythmias, and coronary artery diseases. These drugs are critical for managing cardiovascular diseases, which are among the leading causes of mortality globally. The necessity of cardiovascular drugs lies in their ability to significantly improve patient outcomes, reduce hospital admissions, and enhance quality of life. Their applications range across managing acute episodes, chronic conditions, and preventive care. End-use scopes include hospitals, clinics, and outpatient services, as well as individual use under prescription.

Key growth drivers in this market include the increasing prevalence of cardiovascular diseases, a rising elderly population, and ongoing advancements in drug development and personalized medicine. Moreover, the surge in demand for effective therapeutic options drives market expansion. The integration of artificial intelligence in drug discovery and development, focusing on precision medicine, offers new growth avenues. However, challenges persist, such as stringent regulatory frameworks, high costs associated with drug development, and potential side effects, which can hinder market growth.

To tap into potential opportunities, stakeholders should focus on innovative drug formulations, including biodegradable stents and drug-eluting balloons. Collaborations between pharmaceutical companies and biotech firms can facilitate research and development of breakthrough therapies. Additionally, investing in digital health technologies for remote patient monitoring and adherence could enhance drug efficacy and patient engagement. Limitations such as the need for extensive clinical trials and the risk of drug recalls remain significant barriers.

For business growth, prioritizing research in gene therapy, RNA-based drugs, and exploring applications of nanotechnology in drug delivery could prove transformational. Overall, the cardiovascular drugs market is poised for innovation, though it requires navigating complex regulatory waters and addressing economic constraints to harness its full potential effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiovascular Drugs Market

The Cardiovascular Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising Prevalence of Cardiovascular Disorders
  • Increasing R&D Investments for Drug Development
  • Government Initiatives for Prevention & Control of Cardiovascular Diseases
• Market Restraints
  • Product Recalls and High Cost of Cardiovascular Drugs
• Market Opportunities
  • Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
  • Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
• Market Challenges
  • Complexities in Efficient and Safe Drug Development

Porter's Five Forces: A Strategic Tool for Navigating the Cardiovascular Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiovascular Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiovascular Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiovascular Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiovascular Drugs Market

A detailed market share analysis in the Cardiovascular Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiovascular Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiovascular Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Gilead Sciences, Inc., Otsuka Holdings Co., Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Chiesi USA, Inc., Cornerstone Therapeutics Inc., Pfizer Inc., Daiichi Sankyo Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Ferring B.V., Sanofi S.A., Novo Nordisk A/S, Boehringer Ingelheim GmbH, Par Pharmaceutical by Endo International, CYTOKINETICS, Incorporated, Bristol-Myers Squibb Company, Bausch Health Companies Inc., Abbott Laboratories, Auro Pharma Inc., WellSpring Pharmaceutical Corporation, Merck KGaA, AstraZeneca PLC, Zydus Group, Baxter International Inc., Apotex Inc., Bayer AG, and Cipla Limited.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic, Antihypertensive, and Antiplatelet Drugs.
• Based on Disease Indication, market is studied across Arrhythmia, Coronary Artery Disease, Hyperlipidaemia, and Hypertension.
• Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
• Based on Mode of Purchase, market is studied across Over-The-Counter Drugs and Prescription-Based Drugs.
• Based on End-Users, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Prevalence of Cardiovascular Disorders
    • 5.1.1.2. Increasing R&D Investments for Drug Development
    • 5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
    • 5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities in Efficient and Safe Drug Development
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
  • 5.2.2. Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
  • 5.2.3. Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
  • 5.2.4. End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cardiovascular Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Angiotensin Inhibitors
• 6.3. Anticoagulants
• 6.4. Antihyperlipidemic
• 6.5. Antihypertensive
• 6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

• 7.1. Introduction
• 7.2. Arrhythmia
• 7.3. Coronary Artery Disease
• 7.4. Hyperlipidaemia
• 7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral
• 8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

• 9.1. Introduction
• 9.2. Over-The-Counter Drugs
• 9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
  • 14.3.2. U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
  • 14.3.3. Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India

Companies Mentioned

• 1. Gilead Sciences, Inc.
• 2. Otsuka Holdings Co., Ltd.
• 3. Novartis AG
• 4. Teva Pharmaceutical Industries Ltd.
• 5. Johnson & Johnson Services, Inc.
• 6. Chiesi USA, Inc.
• 7. Cornerstone Therapeutics Inc.
• 8. Pfizer Inc.
• 9. Daiichi Sankyo Co., Ltd.
• 10. Eli Lilly and Company
• 11. F. Hoffmann-La Roche Ltd.
• 12. Eisai Co., Ltd.
• 13. Ferring B.V.
• 14. Sanofi S.A.
• 15. Novo Nordisk A/S
• 16. Boehringer Ingelheim GmbH
• 17. Par Pharmaceutical by Endo International
• 18. CYTOKINETICS, Incorporated
• 19. Bristol-Myers Squibb Company
• 20. Bausch Health Companies Inc.
• 21. Abbott Laboratories
• 22. Auro Pharma Inc.
• 23. WellSpring Pharmaceutical Corporation
• 24. Merck KGaA
• 25. AstraZeneca PLC
• 26. Zydus Group
• 27. Baxter International Inc.
• 28. Apotex Inc.
• 29. Bayer AG
• 30. Cipla Limited